GlaxoSmithKline Book Value per Share: 5.21
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
GSK Book Value per Share Rankings
| Overall | 33rd percentile | 3022 of 4556 |
| Sector | 61st percentile | 200 of 518 in Healthcare |
| Industry | 53rd percentile | 12 of 26 in Drug Manufacturers - Major |
GSK Book Value per Share Range, Past 5 Years
| Minimum | 3.22 | Mar 2004 |
| Maximum | 6.10 | Sep 2006 |
| Average |
About Book Value per Share
Book value per share indicates the book value (or accounting value) of each share of stock. Book value is a company's net asset value, which is calculated by total assets minus intangible assets and liabilities. A relatively high book value per share in relation to stock price often occurs when a stock is undervalued.
In the rare circumstance that market price falls below the book value per share, generally a stock is undervalued and might be an attractive buy.
Learn More
You may also be interested in these GSK related companies
GSK News
Interesting to see $GSK boasting about how it is repatriates its cash from European operations so fast these days. Probably a wise move.
about 5 days ago by bradloncar
about 5 days ago by bradloncar
GlaxoSmithKline plc's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Feb 07, 3:30PM Seeking Alpha
Feb 07, 3:30PM Seeking Alpha
Siemens Forms New Companion Diagnostics Partnerships with ViiV Healthcare and Tocagen
Feb 07, 11:33AM PR Newswire
Feb 07, 11:33AM PR Newswire
$GSK IR on Twitter. Smart example. "GSK to announce 2011 year-end results [today] at noon GMT. We'll be using the hashtag #GSKFY11"
about 6 days ago by BHSMITH
about 6 days ago by BHSMITH
Anacor Pharmaceuticals Down 14.4% After GlaxoSmithKline Pauses Ongoing Trials
Feb 06, 9:20AM Benzinga
Feb 06, 9:20AM Benzinga
Glaxo (GSK) Halts Enrollment in GSK '052 Phase 2b Following Recent Discovery (ANAC)
Feb 06, 8:31AM Street Insider
Feb 06, 8:31AM Street Insider
$ANAC reports partner GlaxoSmithKline $GSK has voluntarily paused enrollment of ongoing GSK '052 Phase 1, 2 Clinical Trials; ANAC halted
about 7 days ago by Street_Insider
about 7 days ago by Street_Insider
Drastic day for healthcare, esp. with pneumonia-deaths in clinical trials! http://stks.co/1qHP $THRX $BMY $GSK $INHX $IDIX
about 34 days ago by juliat333
about 34 days ago by juliat333
$GSK http://stks.co/1oDf $GSK looking intersting here, looking @ Feb 46 call or ITM 45's
about 38 days ago by _TheBlackSwan_
about 38 days ago by _TheBlackSwan_
RT @BloombergNews Drug approvals hit a seven-year high | http://stks.co/1n8c $GSK $JNJ
about 38 days ago by brittpierpoint
about 38 days ago by brittpierpoint
@Dostoevsky $HGSI has a few other drugs in development, in addition to a long-term relationship with $GSK
about 54 days ago by samlee22
about 54 days ago by samlee22
$GSK to sell 17 OTC brands in North America to $PBH for $660M; PBH shares up 7.8% pre-open
about 55 days ago by Street_Insider
about 55 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GSK | 44.75 | -0.31 | -0.69% | 114.07B |
| ALNY | 12.15 | -0.90 | -6.90% | 519.17M |
| CTIC | 1.08 | -0.02 | -1.82% | 208.31M |
| GOOG | 605.91 | -5.55 | -0.91% | 196.25B |
| LLNW | 3.98 | -0.12 | -2.81% | 453.32M |
| FITB | 13.35 | -0.17 | -1.29% | 12.27B |
| ASEI | 77.02 | 8.74 | 12.80% | 687.02M |
| MSFT | 30.50 | -0.28 | -0.89% | 256.53B |
| BRCD | 5.80 | -0.14 | -2.36% | 2.85B |
| CSCO | 19.89 | -0.10 | -0.53% | 106.74B |